Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Aristolochic Acid in the Etiology of Renal Cell Carcinoma.

Hoang ML, Chen CH, Chen PC, Roberts NJ, Dickman KG, Yun BH, Turesky RJ, Pu YS, Vogelstein B, Papadopoulos N, Grollman AP, Kinzler KW, Rosenquist TA.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1600-1608. Epub 2016 Aug 23.

2.

Aristolochic acid-associated urothelial cancer in Taiwan.

Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):8241-6. doi: 10.1073/pnas.1119920109. Epub 2012 Apr 9.

3.

Aristolochic acid exposure in Romania and implications for renal cell carcinoma.

Turesky RJ, Yun BH, Brennan P, Mates D, Jinga V, Harnden P, Banks RE, Blanche H, Bihoreau MT, Chopard P, Letourneau L, Lathrop GM, Scelo G.

Br J Cancer. 2016 Jan 12;114(1):76-80. doi: 10.1038/bjc.2015.402. Epub 2015 Dec 10.

4.

Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.

Jelaković B, Castells X, Tomić K, Ardin M, Karanović S, Zavadil J.

Int J Cancer. 2015 Jun 15;136(12):2967-72. doi: 10.1002/ijc.29338. Epub 2014 Dec 10.

5.

Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.

Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS.

Int J Cancer. 2013 Jul;133(1):14-20. doi: 10.1002/ijc.28013. Epub 2013 Feb 12.

6.

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG.

Kidney Int. 2012 Mar;81(6):559-67. doi: 10.1038/ki.2011.371. Epub 2011 Nov 9.

7.

Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.

Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ.

Chem Res Toxicol. 2012 May 21;25(5):1119-31. doi: 10.1021/tx3000889. Epub 2012 May 4.

8.

Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.

Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM.

Int J Cancer. 2014 Jul 15;135(2):502-7.

PMID:
24921086
9.

Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.

Arlt VM, Stiborova M, Schmeiser HH.

Mutagenesis. 2002 Jul;17(4):265-77. Review.

PMID:
12110620
10.

Mutational signature of aristolochic acid: Clue to the recognition of a global disease.

Rosenquist TA, Grollman AP.

DNA Repair (Amst). 2016 Aug;44:205-211. doi: 10.1016/j.dnarep.2016.05.027. Epub 2016 May 20. Review.

PMID:
27237586
11.

DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver.

Mei N, Arlt VM, Phillips DH, Heflich RH, Chen T.

Mutat Res. 2006 Dec 1;602(1-2):83-91. Epub 2006 Sep 28.

12.

Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.

Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S.

Environ Mol Mutagen. 2012 Oct;53(8):636-41. doi: 10.1002/em.21732. Epub 2012 Sep 17.

PMID:
22987305
13.

Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis.

Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, Shibutani S.

Drug Metab Dispos. 2006 Jul;34(7):1122-7. Epub 2006 Apr 12.

PMID:
16611860
14.

Human formalin-fixed paraffin-embedded tissues: an untapped specimen for biomonitoring of carcinogen DNA adducts by mass spectrometry.

Yun BH, Rosenquist TA, Nikolić J, Dragičević D, Tomić K, Jelaković B, Dickman KG, Grollman AP, Turesky RJ.

Anal Chem. 2013 May 7;85(9):4251-8. doi: 10.1021/ac400612x. Epub 2013 Apr 10.

15.

Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.

Hollstein M, Moriya M, Grollman AP, Olivier M.

Mutat Res. 2013 Jul-Sep;753(1):41-9. doi: 10.1016/j.mrrev.2013.02.003. Epub 2013 Feb 17. Review.

16.

Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts.

Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Schärer OD, Grollman AP.

Nucleic Acids Res. 2012 Mar;40(6):2494-505. doi: 10.1093/nar/gkr1095. Epub 2011 Nov 25.

17.

Chemical and molecular basis of the carcinogenicity of Aristolochia plants.

Schmeiser HH, Stiborovà M, Arlt VM.

Curr Opin Drug Discov Devel. 2009 Jan;12(1):141-8. Review.

PMID:
19152223
18.

Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.

Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT.

Sci Transl Med. 2013 Aug 7;5(197):197ra101. doi: 10.1126/scitranslmed.3006086.

19.

Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.

Grollman AP.

Environ Mol Mutagen. 2013 Jan;54(1):1-7. doi: 10.1002/em.21756. Epub 2012 Dec 13. Review.

PMID:
23238808
20.

Selective toxicity of aristolochic acids I and II.

Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP.

Drug Metab Dispos. 2007 Jul;35(7):1217-22. Epub 2007 Mar 28.

PMID:
17392392

Supplemental Content

Support Center